{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:16:37Z","timestamp":1788405397868,"version":"build-2803163510"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Am Acad Orthop Surg","JAAOS"],"published-print":{"date-parts":[[2023,5,15]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Bone anabolic agents can benefit orthopaedic patients perioperatively and improve outcomes after fragility fractures. However, preliminary animal data raised concern for the potential development of primary bony malignancies after treatment with these medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This investigation examined 44,728 patients older than 50 years who were prescribed teriparatide or abaloparatide and compared them with a matched control group to evaluate risk of primary bone cancer development. Patients younger than 50 years with a history of cancer or other risk factors of bony malignancy were excluded. A separate cohort of 1,241 patients prescribed an anabolic agent with risk factors of primary bone malignancy, along with 6,199 matched control subjects, was created to evaluate the effect of anabolic agents. Cumulative incidence and incidence rate per 100,000 person-years were calculated as were risk ratios and incidence rate ratios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The overall risk of primary bone malignancy development for risk factor\u2013excluded patients in the anabolic agent-exposed group was 0.02%, compared with 0.05% in the nonexposed group. The incidence rate per 100,000 person-years was calculated at 3.61 for the anabolic-exposed patients and 6.46 for control subjects. A risk ratio of 0.47 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03) and incidence rate ratio of 0.56 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.052) were observed for the development of primary bone malignancies in patients undergoing treatment with bone anabolic agents. Among high-risk patients, 5.96% of the anabolic-exposed cohort developed primary bone malignancies and 8.13% of nonexposed patients developed primary bone malignancy. The risk ratio was 0.73 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01), and the incidence rate ratio was 0.95 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.67).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Teriparatide and abaloparatide can safely be used for osteoporosis and orthopaedic perioperative management without increased risk of development of primary bone malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5435\/jaaos-d-22-01094","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T15:00:06Z","timestamp":1678719606000},"page":"520-528","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of Osteoporosis With Anabolic Agents and the Risk of Primary Bone Cancers: A Study of 44,728 Patients Treated With Teriparatide and Abaloparatide"],"prefix":"10.5435","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9633-5336","authenticated-orcid":false,"given":"Christopher L.","family":"McDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keir","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8754-7070","authenticated-orcid":false,"given":"Daniel","family":"Alsoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Molino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah","family":"Balmaceno-Criss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PAP.0000000000000293","article-title":"The 2020 WHO classification of tumors of bone: An updated review","volume":"28","author":"Choi","year":"2021","journal-title":"Adv Anat Pathol"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10552-015-0607-3","article-title":"Bone cancer incidence by morphological subtype: A global assessment","volume":"26","author":"Valery","year":"2015","journal-title":"Cancer Causes Control"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(09)70286-4","article-title":"Ewing's sarcoma","volume":"11","author":"Balamuth","year":"2010","journal-title":"Lancet Oncol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2007-0237","article-title":"The clinical approach towards chondrosarcoma","volume":"13","author":"Gelderblom","year":"2008","journal-title":"The Oncologist"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/ijc.33673","article-title":"International trends in incidence of osteosarcoma (1988-2012)","volume":"149","author":"Rojas","year":"2021","journal-title":"Int J Cancer"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2018.11.027","article-title":"Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1 (European and American osteosarcoma study) cohort","volume":"109","author":"Smeland","year":"2019","journal-title":"Eur J Cancer"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/ng.2645","article-title":"Genome-wide association study identifies two susceptibility loci for osteosarcoma","volume":"45","author":"Savage","year":"2013","journal-title":"Nat Genet"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bone.2016.10.017","article-title":"Molecular genetics of osteosarcoma","volume":"102","author":"Rickel","year":"2017","journal-title":"Bone"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"E2130","DOI":"10.3390\/cancers12082130","article-title":"Molecular biology of osteosarcoma","volume":"12","author":"Czarnecka","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv101","article-title":"Germline TP53 variants and susceptibility to osteosarcoma","volume":"107","author":"Mirabello","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R12-20250503","first-page":"1","article-title":"TP53 mutations and survival in osteosarcoma patients: A meta-analysis of published data","volume":"2016","author":"Chen","year":"2016","journal-title":"Dis Markers"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1200\/JCO.1996.14.2.467","article-title":"Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma","volume":"14","author":"Feugeas","year":"1996","journal-title":"JCO"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1073\/pnas.82.18.6216","article-title":"Osteosarcoma and retinoblastoma: A shared chromosomal mechanism revealing recessive predisposition","volume":"82","author":"Hansen","year":"1985","journal-title":"Proc Natl Acad Sci"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/(SICI)1097-0215(19980729)77:3<370::AID-IJC11>3.0.CO;2-C","article-title":"Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood","volume":"77","author":"Le Vu","year":"1998","journal-title":"Int J Cancer"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2045-3329-2-18","article-title":"Sarcoma risk after radiation exposure","volume":"2","author":"Berrington de Gonzalez","year":"2012","journal-title":"Clin Sarcoma Res"},{"key":"R17-20250503","first-page":"153","article-title":"Secondary osteosarcoma in patients previously treated for childhood cancer: Three case reports","volume":"10","author":"Shimatani","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11912-018-0658-1","article-title":"Primary osteosarcoma in the elderly revisited: Current concepts in diagnosis and treatment","volume":"20","author":"Kumar","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00003086-199201000-00028","article-title":"Second cancers in long-term survivors of Ewing's sarcoma","volume":"274","author":"Smith","year":"1992","journal-title":"Clin Orthop Relat Res"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jbmr.4188","article-title":"Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study","volume":"36","author":"Gilsenan","year":"2021","journal-title":"J Bone Miner Res"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/BSD.0000000000000810","article-title":"Is teriparatide beneficial to spinal fusion surgery in the older patient?","volume":"32","author":"Wanderman","year":"2019","journal-title":"Clin Spine Surg A Spine Publ"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/BRS.0000000000003512","article-title":"Evidence-based recommendations for spine surgery","volume":"45","author":"Fisher","year":"2020","journal-title":"Spine"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.wneu.2016.11.135","article-title":"Evidence for use of teriparatide in spinal fusion surgery in osteoporotic patients","volume":"100","author":"Chaudhary","year":"2017","journal-title":"World Neurosurg"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"106244","DOI":"10.1016\/j.clineuro.2020.106244","article-title":"Use of teriparatide prior to lumbar fusion surgery lowers two-year complications for patients with poor bone health","volume":"198","author":"Yolcu","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.arth.2017.07.026","article-title":"Teriparatide administration increases periprosthetic bone mineral density after total knee arthroplasty: A prospective study","volume":"33","author":"Suzuki","year":"2018","journal-title":"J Arthroplasty"},{"key":"R27-20250503","first-page":"32","article-title":"Teriparatide treatment improved loosening of cementless total knee arthroplasty: A case report","volume":"7","author":"Suzuki","year":"2017","journal-title":"J Orthop Case Rep"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11926-013-0371-x","article-title":"Osteoporosis and orthopedic surgery: Effect of bone health on total joint arthroplasty outcome","volume":"15","author":"Russell","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00198-017-4286-7","article-title":"Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur","volume":"29","author":"Greenspan","year":"2018","journal-title":"Osteoporos Int"},{"issue":"suppl 1","key":"R30-20250503","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0020-1383(16)30009-2","article-title":"Use of teriparatide in osteoporotic fracture patients","volume":"47","author":"Collinge","year":"2016","journal-title":"Injury"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/pds.5103","article-title":"Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data","volume":"29","author":"Gilsenan","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/BCO.0000000000000405","article-title":"Global incidence of primary malignant bone tumors","volume":"27","author":"Kumar","year":"2016","journal-title":"Curr Orthop Pract"}],"container-title":["Journal of the American Academy of Orthopaedic Surgeons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-22-01094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:47:02Z","timestamp":1787669222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-22-01094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5435\/jaaos-d-22-01094","relation":{},"ISSN":["1067-151X","1940-5480"],"issn-type":[{"value":"1067-151X","type":"print"},{"value":"1940-5480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"assertion":[{"value":"2022-11-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}